Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells. (March 2019)

• Record Type: Journal Article
• Authors: Friedman, Jay; Padget, Michelle; Lee, John; Schlom, Jeffrey; Hodge, James; Allen, Clint
• Is Part Of: Oral oncology. Volume 90(2019)
• Page Start: 38
• Page End: 44
• Publication Date: 2019-03
• Subjects: haNK -- Radiation -- ADCC -- Head and neck cancer -- Cetuximab -- Avelumab; Mouth -- Cancer -- Periodicals; Mouth -- Tumors -- Periodicals; Mouth Diseases -- Periodicals; Mouth Neoplasms -- Periodicals; Bouche -- Cancer -- Périodiques; Bouche -- Tumeurs -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9943105
• DOI: 10.1016/j.oraloncology.2019.01.017
• Languages: English
• ISSNs: 1368-8375

Abstract

Highlights: haNKs are an off-the-shelf cellular therapy that kill head and neck cancer cells. Cetuximab and Avelumab enhance tumor cell killing by haNKs through ADCC. Ionizing radiation may enhance ADCC through increased expression of antibody targets. haNKs plus cetuximab or avelumab warrant evaluation in clinical trials for HNSCC. Abstract: High affinity natural killer cells (haNKs) are a cell therapy product capable of mediating both direct and antibody-dependent cell-mediated cytotoxicity (ADCC). These cells may be particularly useful in tumors that escape T-cell anti-tumor immunity by harboring antigen processing and presentation defects. Here, we demonstrated that haNKs directly kill both HPV-positive and negative head and neck squamous cell carcinoma cells. Variable tumor cell sensitivity to haNK direct cytotoxicity did not correlated with MHC class I chain-related protein A or B (MICA or MICB) expression. Importantly, haNK killing was significantly enhanced via ADCC mediated by cetuximab or avelumab in cells with higher baseline EGFR or PD-L1 expression, respectively. The ability of IFNγ to induce tumor cell PD-L1 expression correlated with enhanced PD-L1-specific ADCC. IFNγ induced neither tumor cell EGFR expression nor EGFR-specific ADCC. Although a single dose of 8 Gy IR did not appear to directly enhance susceptibility to haNK killing alone, enhanced PD-L1- and EGFR-mediated ADCC after IR correlated with increased PD-L1 and EGFR expression in one of four models. This pre-clinical evidence supports the investigation of haNK cellular therapy in combination with ADCC-mediating mAbs, with or without IR, in the clinical trial setting for patients with advanced HNSCCs. Given the MHC-unrestricted nature of this treatment, it may represent an opportunity to treat patients with non-T-cell inflamed tumors.